Sequential cancer immunotherapy: targeted activity of dimeric TNF and IL-8 by Bauer, S et al.
University of Zurich





Sequential cancer immunotherapy: targeted activity of dimeric
TNF and IL-8
Bauer, S; Adrian, N; Siebenborn, U; Fadle, N; Plesko, M; Fischer, E; Wüest, T;
Stenner, F; Mertens, J C; Knuth, A; Ritter, G; Old, L J; Renner, C
Bauer, S; Adrian, N; Siebenborn, U; Fadle, N; Plesko, M; Fischer, E; Wüest, T; Stenner, F; Mertens, J C; Knuth, A;




Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Cancer Immunity 2009, 9(2):1-10.
Bauer, S; Adrian, N; Siebenborn, U; Fadle, N; Plesko, M; Fischer, E; Wüest, T; Stenner, F; Mertens, J C; Knuth, A;




Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Cancer Immunity 2009, 9(2):1-10.
Sequential cancer immunotherapy: targeted activity of dimeric
TNF and IL-8
Abstract
 Polymorphonuclear neutrophils (PMNs) are potent effectors of inflammation and their attempts to
respond to cancer are suggested by their systemic, regional and intratumoral activation. We previously
reported on the recruitment of CD11b+ leukocytes due to tumor site-specific enrichment of TNF activity
after intravenous administration of a dimeric TNF immunokine with specificity for fibroblast activation
protein (FAP). However, TNF-induced chemo-attraction and extravasation of PMNs from blood into the
tumor is a multistep process essentially mediated by interleukin 8. With the aim to amplify the
TNF-induced and IL-8-mediated chemotactic response, we generated immunocytokines by N-terminal
fusion of a human anti-FAP scFv fragment with human IL-8 (IL-8(72)) and its N-terminally truncated
form IL-8(3-72). Due to the dramatic difference in chemotaxis induction in vitro, we favored the mature
chemokine fused to the anti-FAP scFv for further investigation in vivo. BALB/c nu/nu mice were
simultaneously xenografted with FAP-positive or -negative tumors and extended chemo-attraction of
PMNs was only detectable in FAP-expressing tissue after intravenous administration of the anti-FAP
scFv-IL-8(72) construct. As TNF-activated PMNs are likewise producers and primary targets for IL-8,
we investigated the therapeutic efficacy of co-administration of both effectors: Sequential application of
scFv-IL-8(72) and dimeric IgG1-TNF fusion proteins significantly enhanced anti-tumor activity when
compared either to a single effector treatment regimen or sequential application of non-targeted
cytokines, indicating that the tumor-restricted sequential application of IL-8(72) and TNF is a promising
approach for cancer therapy.
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inflammation and their attempts to respond to cancer are suggested 
by their systemic, regional and intratumoral activation. We 
previously reported on the recruitment of CD11b+ leukocytes due to 
tumor site-specific enrichment of TNF activity after intravenous 
administration of a dimeric TNF immunokine with specificity for 
fibroblast activation protein (FAP). However, TNF-induced chemo-
attraction and extravasation of PMNs from blood into the tumor is a 
multistep process essentially mediated by interleukin 8. With the aim 
to amplify the TNF-induced and IL-8-mediated chemotactic 
response, we generated immunocytokines by N-terminal fusion of a 
human anti-FAP scFv fragment with human IL-8 (IL-872) and its 
N-terminally truncated form IL-83-72. Due to the dramatic difference 
in chemotaxis induction in vitro, we favored the mature chemokine 
fused to the anti-FAP scFv for further investigation in vivo. BALB/c 
nu/nu mice were simultaneously xenografted with FAP-positive or 
-negative tumors and extended chemo-attraction of PMNs was only 
detectable in FAP-expressing tissue after intravenous administration 
of the anti-FAP scFv-IL-872 construct. As TNF-activated PMNs are 
likewise producers and primary targets for IL-8, we investigated the 
therapeutic efficacy of co-administration of both effectors: 
Sequential application of scFv-IL-872 and dimeric IgG1-TNF fusion 
proteins significantly enhanced anti-tumor activity when compared 
either to a single effector treatment regimen or sequential 
application of non-targeted cytokines, indicating that the tumor-
restricted sequential application of IL-872 and TNF is a promising 
approach for cancer therapy.
Keywords: mice, anti-FAP scFv, IL-8, TNF, recombinant fusion 
protein, polymorphonuclear neutrophils 
Introduction
The therapeutic use of cytokines as anticancer drugs is greatly 
limited in the clinic by their lack of tumor specificity causing 
unselective side effects outside the tumor environment. These 
non-specific activities result in a narrow therapeutic window 
with a low therapeutic index. Therefore, the most critical issue 
in order to improve therapeutic efficacy is the increase of local 
cytokine concentrations at the tumor site, together with the 
minimization of unwanted side effects. Fusing cytokines to 
tumor-associated antigen-specific antibodies offers an 
alternative strategy to achieve the goal of locally restricted 
cytokine enrichment. Fusion proteins can preserve their 
targeting properties (determined by the monoclonal antibody 
domain), remain mostly inactive in circulation and induce 
cytokine-mediated anti-tumor effects when reaching the target 
site (1).
The prototype of a cytokine that possesses a wide range of 
potent biological anti-tumor activities is tumor necrosis factor 
(TNF). Since its systemic administration mediated the 
regression of sarcomas in mice (2), TNF has attracted attention 
as a potential anti-tumor reagent (3). However, the problem of 
dose-limiting toxicity has been particular apparent in human 
trials with a 40-fold lower maximal tolerated dose in humans 
than in mice (4, 5) and systemic administration resulted in life-
threatening side effects (6). Nevertheless, its more localized 
delivery by isolated limb perfusion mediated very impressive 
tumor regressions (7) and spurred the design of a clinically 
applicable cytokine format. To this aim, our strategy relied on 
the alteration of the natural TNF homotrimeric symmetry by 
linking a TNF molecule to the C-terminus of each CH1 domain 
of a human IgG antibody. These fusion proteins preserved the 
characteristic IgG-dimeric structure with two TNF subunits (8). 
The dimeric TNF structure resulted in significantly reduced 
toxicity as seen both in immunocompetent and -deficient 
mouse strains and could, therefore, display significantly 
stronger anti-tumor activity when compared with trimeric TNF 
and its conjugates (9). Moreover, the IgG-derived dimeric 
design represented a structural principle for targeted 
immunotherapy of multiple tumor entities, as accumulation of 
TNF depends on the antigen specificity of the fused antibodies 
(10). Accumulation of dimeric TNF in the microenvironment of 
xenotransplanted tumors in nude mice activated multiple 
tumoricidal effector mechanisms, including alteration of the 
natural tumor to polymorphonuclear neutrophils (PMNs) 
balance due to recruitment and activation of CD11b+ 
leukocytes (8). However, TNF-induced chemo-attraction and 
extravasation of PMNs from blood into the tumor is a multistep 
process that is mainly IL-8-dependent (11, 12). The most 
abundant naturally occurring form of IL-8 is a 72-residue 
protein derived by processing a 99-residue precursor (13, 14). In 
addition, several alternatively processed amino-terminal 
variants have been detected; the IL-83-72 variant was described 
to display a two-fold higher neutrophil chemotaxis activity (15). 
Therefore, we fused a human anti-FAP scFv fragment to either 
the 72-residue human IL-8 or the human IL-83-72 variant in 1 of 10
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Preparation and characterization of scFv constructs. (A) Scheme of the constructs for anti-FAP scFv, anti-FAP scFv-IL-872 and anti-FAP scFv-IL-83-72 as they were 
inserted into the mammalian expression vector pEAK8. The anti-FAP scFv antibody vector consisted of the promoter-leader cassette coding for an 18-aa secretory leader 
sequence, the variable heavy chain region followed by a 10-aa linker with the light chain variable region and a DNA sequence encoding a c-myc and His6 tag at the C-ter-
minus for detection and affinity purification. IL-8 variants are N-terminally linked to anti-FAP scFv by (Ser4Gly)3. (B) Anti-FAP scFv-IL-8 (lanes 1 to 3) and anti-FAP 
scFv-IL-83-72 (lanes 4 to 6) were purified by immobilized metal chelate chromatography. Culture supernatant (lanes 1 and 4), flow through (lanes 2 and 5) and purified 
constructs (lanes 3 and 6) were analyzed by SDS-PAGE under reducing conditions. As expected, bands corresponding to scFv IL-8 variants were detected at 39 kDa (lane 
3 for anti-FAP scFv-IL-872 and lane 6 for anti-FAP scFv-IL-83-72). (C) Western blot analysis of anti-FAP scFv (lanes 1 and 4), anti-FAP scFv-IL-872 (lanes 2 and 5) and 
anti-FAP scFv IL-83-72 (lanes 3 and 6) stained with anti-c-myc (lanes 1 to 3) and anti-hu IL-8 antibody (lanes 4 to 6).
order to amplify the TNF-induced, but IL-8-mediated 
chemotactic response. IL-8-derived constructs were 
characterized in vitro and fibroblast activation protein (FAP)-
expressing tumors served as a model for targeted delivery of 
antibody-fused TNF and IL-8 in vivo. Sequential 
administration of both immunocytokines resulted in 
significantly improved therapeutic efficacy due to enhanced 
PMN recruitment to xenografted tumors in BALB/c nu/nu mice 
when compared to the application of each construct alone or 
non-targeted effector molecules.
Results
Generation, biochemical characterization and binding of IL-8-
derived fusion proteins
To generate the single-chain IL-8-derived fusion proteins, the 
cDNA of hu IL-872 and hu IL-83-72 were fused to a 45-bp linker 
at the 3' end of the previously described anti-FAP scFv (9) 
(Figure 1A). Constructs were cloned into the pEAK mammalian 
expression vector and confirmed by DNA sequencing. 
Transfection of suspension-adapted HEK293 EBNA cells (16) 
was performed in spinner flasks using an optimized calcium 
phosphate precipitation method (17). Fusion proteins were 
purified from the supernatant with a final yield of 40 mg/l 
culture. Constructs were analyzed by gel electrophoresis and 2 of 10 www.cancerimmunity.org
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Binding properties of scFv constructs. (A) Flow cytometry analysis of constructs [anti-FAP scFv (thick line), anti-FAP scFv-IL-83-72 (dotted line) and anti-FAP scFv-
IL-872 (thin line)] was performed on FAP-transfected HT1080 cells. An anti-CD30 scFv-IL-8 fusion protein served as negative control. Binding was detected by mono-
clonal anti-c-myc antibody. (B) Recognition of targeted antigen by scFv constructs was performed by incubation with rabbit anti-human IL-8 and visualized by PE-con-
jugated goat anti-rabbit serum. Uncoupled parental anti-CD30 scFv-IL-8 was used as negative control. (C) Binding of scFv variants to immobilized anti-FAP-anti-ID was 
visualized by rabbit anti-IL-8 serum using ELISA. Uncoupled anti-FAP scFv and anti-CD30 scFv-IL-8 were used as controls. Measurements were carried out in triplicate 
samples; standard deviations are indicated by the bars.
Figure 3 
Chemotactic potential of anti-FAP scFv-IL-8 variants in vitro. We used a fluo-
rescence-based end-point assay to measure PMN migration in vitro. Chemo-
attractants (rhu IL-8, anti-FAP scFv, anti-FAP scFv-IL-83-72 and anti-FAP scFv-IL-
872) and controls were diluted in PBS-HSA 0.1%. PBS-HSA 0.1% alone was used 
to determine random migration. In order to define the total fluorescence of 
PMNs, calcein-AM labeled PMNs were placed directly at defined concentrations 
(80000, 8000, 800 and 80 cells) in three separate wells. 80000 PMNs were placed 
directly onto the top of the filter and the chamber was incubated for 60 minutes. 
The total number of PMNs that had migrated to the lower chamber was measured 
with a fluorescence plate reader. Measurements were carried out in triplicate sam-
ples. The standard deviation of three assays is shown.
Western blotting using an anti-IL-8 and anti-c-myc antibody for 
detection. The IL-8-derived single chain antibody constructs 
revealed a molecular size of 39 kDa under reducing conditions 
(Figure 1B). Western blotting of SDS gels and staining with 
anti-c-myc antibody identified the tagged constructs. As 
expected, staining with anti-IL-8 antibody failed to detect anti-
FAP scFv (Figure 1C).
The immunoreactivity of the IL-8 fusion proteins was assessed 
by flow cytometry. Anti-FAP moieties were demonstrated on 
FAP- and mock-transfected HT1080 cells using either the anti-
c-myc (Figure 2A) or anti-IL-8 antibody (Figure 2B), 
respectively. Affinity of anti-FAP scFv was higher when 
compared to both IL-8 immunocytokines, showing equal 
binding properties. The integrity of the IL-8-derived constructs 
was confirmed by sandwich ELISA with simultaneous 
recognition of the IL-8 moiety by an anti-human IL-8 antibody 
and binding of the antibody moiety to a murine anti-idiotypic 
anti-FAP mAb (Figure 2C)www.cancerimmunity.org 3 of 10
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Kinetics of FAP expression of transfected HT1080-FAP+ fibrosarcoma cells in vitro and in vivo. (A) FAP transfected HT1080 cells were cultured without G418 selec-
tive pressure and the levels of antigen density were measured after 3 weeks by FACScan analysis. (B to E) Immunohistochemical staining of HT1080-FAP+ xenograft fib-
rosarcoma cells showing positive staining over a period of four weeks. 5 x 106 cells were injected s.c. in BALB/c nu/nu mice. Solid tumors were harvested after 14 (B, C) 
and 28 days (D, E), respectively. Tissue sections were stained with anti-FAP IgG (B, D) or with anti-G250 IgG (C, E) as a control. Bars correspond to 10 µm.
Chemotactic potential of anti-FAP scFv-IL-8 fusion proteins in vitro
PMNs from the venous blood of healthy human donors were 
labeled with calcein and PMN migration towards IL-8-derived 
constructs was quantified in vitro using a standardized 
fluorescence-based assay in a chemotaxis chamber in disposable 
96-well microplates. With regard to different molarities of scFv-
fused IL-8 derivates and recombinant human IL-8, chemotaxis 
assays were performed at IL-8-equivalent doses (Figure 3). The 
chemotactic activities of recombinant human (rhu) IL-8 and 
anti-FAP scFv-IL-872 were nearly identical. Both substances 
revealed concentration-dependent migration of PMNs. 
Surprisingly, migration of PMNs towards the scFv-coupled 3-72 
isoform of IL-8 was not superior to the migration towards anti-
FAP scFv which lacks the capability of specific chemo-
attraction. In accordance with published data from other groups 
(18), we could not detect PMN migration towards a TNF 
gradient, neither when used as trimeric rhu TNF nor as dimeric 
antibody-fused TNF. Furthermore, we did not observe additive 
effects of TNF and IL-8 in stimulating PMN migration across 
the filter (data not shown).
Tumor model, PMN recruitment and therapeutic efficacy of anti-
FAP scFv-IL-872
In cell culture, incessant FAP expression of transfected 
HT1080 cells was detectable over several weeks without G418 
selective pressure (Figure 4A). The stability of FAP expression 
was the prerequisite for in vivo targeting of FAP in BALB/c nu/
nu mice xenografted with FAP- or mock-transfected human 
HT1080 fibrosarcoma cells. FAP-positive and -negative tumors 
were simultaneously established on opposite flanks of mice and 
FAP expression could be demonstrated for the entire period of 
targeted treatment (Figure 4B). Due to its superior chemotactic 4 of 10 www.cancerimmunity.org
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Targeted antigen-dependent recruitment of PMNs to FAP-expressing tumors. Fibrosarcomas were established in BALB/c nu/nu mice by s.c. injection of 5 x 106 FAP-
transfected and mock-transfected HT1080 cells, respectively. FAP-positive (left column) and -negative (right column) tumors were simultaneously established at the 
opposite flanks of the animals. Tumors were harvested 24 hours after i.v. injection of a total dose of 300 µg scFv-IL872 (equivalent to 100 µg rhu IL-8). (A, B) FAP expres-
sion of xenografts was confirmed by anti-FAP mAb staining. PECAM-1-positive tumor vessels were visualized to define comparable areas of FAP-positive (C) or 
-negative (D) fibrosarcomas to exclude unspecific PMN accumulation. Staining with anti-CD11b mAb demonstrated the targeted antigen-specific delivery of scFv-IL872
by chemokine-triggered enrichment of PMNs (E, F). Bars correspond to 100 µm.
potency in vitro, the full-length IL-872 scFv construct was tested 
for FAP-specific chemo-attraction of PMNs. Mice 
simultaneously bearing FAP-positive and -negative tumors were 
treated with effector construct equivalent doses of intravenously 
administered anti-FAP scFv-IL-872, rhu IL-8 or anti-FAP scFv, 
respectively. Enrichment of CD11b+ PMNs within FAP-
expressing tumors was only seen in mice properly treated with 
anti-FAP scFv-IL-872. Furthermore, PMN recruitment was 
specific for the targeted antigen as no migration was seen 
towards FAP-negative tumors. Neither the application of 
uncoupled rhu IL-8, nor of the anti-FAP scFv alone could 
induce PMN recruitment towards fibrosarcoma cells, 
irrespective of their FAP expression status (Figure 5).
As PMNs are likewise producers and primary targets for IL-8, 
sequential targeted enrichment of scFv-IL-872 and IgG-TNF 
might raise the chance to initiate an activation loop in chemo-
attracted PMNs, thereby improving the focused therapeutic 
activity. To test the efficacy of the targeted TNF and IL-872
combination regimen, we adopted our well-proven schedule for 
the treatment of BALB/c nu/nu mice with dimeric anti-FAP 
IgG-TNF (8). Both the TNF-equivalent dose of anti-FAP IgG-
TNF and the treatment schedule were excellently tolerated by 
the animals without significant side effects and PMN 
recruitment at targeted tumor sites was detectable within 24 
hours following administration (8, 9). Since TNF and IL-8 are 
key components in the promotion of generalized endothelial 
activation leading to systemic inflammatory response syndrome 
(SIRS) (19), we favored a sequential schedule with an eight-hour 
time interval between the administrations of each targeted 
cytokine to minimize unwanted peripheral activation of PMNs 
and endothelial cells. The delay of eight hours was feasible since 
the half-life of IgG antibodies is mainly determined by the CH2/
CH3 constant regions and their exchange by TNF causes a rapid 
clearance rate of dimeric antibody-fused TNF 
immunocytokines (10). Treatment of mice started on day nine 
after tumor cell inoculation and was carried out over a period of 
two weeks with five consecutive treatment days (Figure 6A). 
Repetitive administration of anti-FAP scFv-IL-872 alone at its 
chemo-attractive dose already results in significant anti-tumor 
effects when compared to the application of unconjugated anti-www.cancerimmunity.org 5 of 10
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Effects of sequential immunotherapy on the growth pattern of tumor xenografts. (A) FAP positive tumors were established in BALB/c nu/nu mice by s.c. injection 
5 x 106 HT1080 FAP+ cells and mice randomly assigned to different treatment groups at day nine. For sequential immunotherapy, effector constructs were injected i.v. 
and followed eight hours later by i.v. injection of the second effector construct as indicated (100 µl per injection). This treatment regimen was repeated every three days 
as highlighted by the arrows (five times in total). Starting on day 21, the growth delay was statistically significant for the anti-FAP TNF & anti-FAP scFv-IL-872 group (*, 
P < 0.001) when compared to all other treatment groups. Comparison of tumor sizes between the anti-FAP TNF and the anti-FAP TNF & rhu IL-8 group and the 
remaining groups was also significant at this time point (**, P < 0.001), but tumor sizes did not differ significantly between the anti-FAP TNF and the anti-FAP TNF & 
rhu IL-8 group. Single agent treatment with anti-FAP scFv-IL-872 also resulted in significant (***, P < 0.001) anti-tumor effects when compared to the rhu IL-8-contain-
ing regimens that did not differ from the PBS group (data not shown). Treatment results stayed significant over the observation period. Animals were taken off study 
when tumor volume exceeded 1 cm3. (B) Delay of tumor growth of mice receiving anti-FAP TNF & anti-FAP scFv IL-8 was linked to antigen expression. Simultaneous 
growth of two phenotypically different xenografts [FAP-positive (closed symbols) and FAP-negative (open symbols)] was established in nude mice and animals assigned 
to their respective treatment group when tumor diameter reached 5 mm. Again, animals were treated with anti-FAP TNF & anti-FAP scFv-IL-872 following the sequen-
tial application schedule indicated by the arrows. Mice had to be taken off study when the volume of FAP-negative xenografts exceeded 1 cm3. At this time point, differ-
ences in tumor size between FAP-positive and -negative xenografts were statistically significant (*, P < 0.001).
FAP-antibody. However, its therapeutic activity was inferior 
when compared to the TNF-derived anti-FAP fusion protein. 
Attempts to enhance the therapeutic potency of anti-FAP IgG-
TNF by adding sequential applications of rhu IL-8 did not 
provide the desired effect. The addition of rhu TNF to scFv-IL-
872 was not feasible because of lethal TNF toxicity at this dose 
level. Only the combination of both cytokines as part of the 
anti-FAP fusion protein and administered by a sequential 
application regimen enhanced the therapeutic impact of the 
single construct and led to a significant delay in tumor growth. 
In addition to its improved therapeutic activity, anti-tumor 
effects were dependent on the presence of the targeted antigen 
and strongly restricted to FAP-expressing tumors (Figure 6B).
Discussion
Genetic fusion of cytokines and tumor-associated antigen-
specific antibodies is a widely accepted strategy for targeted 
anti-cancer therapy (20, 21). Further development of mono-
therapeutic approaches has led to the combined application of 
cooperatively acting fusion proteins displaying superior anti-
tumor effects when compared to single effector molecule 
treatment (22, 23). We hypothesized that successful 
immunotherapy of FAP-positive tumors with our dimeric anti-
FAP IgG-TNF construct could be further enhanced by 
sequential application of anti-FAP scFv-fused IL-8. Based on 
data about chemically synthesized IL-8 analogues (15), we 
generated two anti-FAP scFv-IL-8 fusion proteins carrying 
different IL-8 isoforms. The structural integrity of N-terminally 
fused IL-8-derived constructs was demonstrated after transient 
mammalian expression and purification. While FAP binding 
was the same for both fusion proteins, the superior antigen 
binding capacity of the parental anti-FAP scFv suggests an 
alteration in the binding specificity by the N-terminal fusion of 
IL-8 variants or by the second linker (24, 25) or a combination of 
both. When fused to anti-FAP scFv, only the mature IL-872
chemokine displayed chemotactic potency comparable to native 
rhu IL-8, while the truncated variant totally failed to induce 6 of 10 www.cancerimmunity.org
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combining an anti-epidermal growth factor receptor F(ab) 
antibody with an N-terminally truncated form of IL-8 (aa 2-72) 
resulted in reduced receptor binding capacity and chemotactic 
activity when compared to rhu IL-8. In this construct, the C-
terminus of the CH1 domain and the N-terminus of IL-8 were 
closely linked by three amino acids and produced in E. coli. 
These factors are thought to be responsible for impaired 
biological activity (26). However, comparison of the biological 
activity of our anti-FAP scFv IL-872 construct and rhu IL8 
clearly revealed equal potency regarding induction of 
chemotaxis. The fact that we did not observe any chemotactic 
activity induced by TNF in vitro is in accordance with data from 
other groups demonstrating the IL-8 dependence of PMN 
migration: i.e. PMN migration across TNF-pre-treated 
endothelium needs active secretion of IL-8 (27, 28). 
Furthermore, transmigration of PMNs properly stimulated by 
TNF could even be completely inhibited by anti-IL-8 antibodies 
(18). In addition to chemotactic activity in vitro, PMN 
recruitment by scFv-fused IL-872 could be demonstrated in vivo
using a nude mouse model. Species cross-reactivity is known for 
human IL-8 and infiltration of xenotransplanted tumors in nude 
mice by murine PMNs has been described upon transfection of 
human ovarian cancer cells with an expression vector coding for 
human IL-8. Furthermore, the study demonstrated a striking 
correlation between IL-8 production, neutrophil-monocyte 
infiltration and regression of xenotransplanted ovarian cancer 
(29). The antibody-based approach simplifies the strategy of 
therapeutic IL-8 release with regard to the clinical situation. 
Administration of anti-FAP scFv-IL-872 resulted in focused 
PMN recruitment localized to xenotransplanted tumors and 
was strictly dependent on the presence of the targeted FAP 
antigen. However, the role of PMNs in anti-tumoral immune 
responses still harbors a striking dichotomy and is currently a 
matter of intensive debate. Under inflammatory conditions, 
PMNs may promote tumor growth and progression, primarily 
in advanced disease (30). In contrast, PMNs can exert important 
tumor-inhibitory activities in the context of therapeutic 
interventions (31, 32). Even in the clinical situation of bladder 
cancer patients treated with bacillus Calmette-Guérin (BCG), 
PMNs are the first and most abundant immune cell 
subpopulation immediately following BCG instillation (33). 
They produce high levels of pro-inflammatory cytokines and 
chemokines, such as IL-8 (34). Furthermore, the extent of 
leukocyte accumulation correlates with a favorable outcome 
after BCG administration (35) and local concentrations of IL-8 
in the bladder were shown to predict clinical responses to BCG 
(36), due to its functional role as an effector cell recruiting 
chemokine (37).
In preclinical models, pivotal anti-tumor mechanisms 
involved in dimeric TNF-based immunotargeting approaches 
also rely on recruitment and side-specific activation of PMNs (8, 
9). In the present approach, sequential administration of IL-8 
and TNF-derived FAP-targeting fusion proteins could 
significantly enhance the therapeutic impact of antibody-bound 
dimeric TNF. This effect is based on the antigen-restricted 
enrichment of PMNs to FAP-positive tumors mediated by IL-8 
and the consecutive specific activation of recruited effector cells 
mediated by TNF. In conclusion, the sequential treatment 
schedule was well tolerated without severe side effects and the 
cytokine-induced activation loop in PMNs displayed significant 
therapeutic activity.
Abbreviations
FAP, fibroblast activation protein; PMN, polymorphonuclear 
neutrophil; rhu, recombinant human
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Materials and methods
Cell lines and reagents
RPMI 1640 medium supplemented with 10% (v/v) heat-
inactivated FCS, penicillin (100 U/ml), streptomycin (0.1 mg/
ml), and glutamine (0.3 mg/ml, all obtained from Invitrogen 
Life Technologies) was used as standard medium. Suspension-
adapted HEK 293 EBNA cells (ATCC) were cultivated in 
spinner flasks in serum-free Ex-Cell VPro medium (JRH, 
Lenexa, USA) at 37°C in a humidified 5% CO2 atmosphere. 
HT1080 FAP-transfected (HT1080-FAP), mock-transfected 
(HT1080) cells and anti-FAP IgG TNF were previously 
described (8). Rat anti-mouse CD11b (clone M1/70) and rat 
anti-mouse platelet endothelial cell adhesion molecule-1 
(PECAM-1; clone MEC13.3) were purchased from BD 
PharMingen (San Diego, CA). Rabbit anti-human IL-8 was from 
Genzyme (Neu-Isenburg, Germany). Biotinylated goat anti-
human IgG was a component of the Vectastain ABC kit (Vector 
Laboratories, Burlingame, CA), biotinylated goat anti-rat IgG 
F(ab)2 and mouse anti-c-myc (clone 9E10.3) were obtained 
from Dianova (Hamburg, Germany). Murine anti-idiotypic 
anti-FAP was from Boehringer Ingelheim. Human recombinant 
TNF and human recombinant IL-8 were purchased from 
Genzyme (Neu-Isenburg, Germany).
Construction of antibody-derived constructs
Reverse transcription PCR on mRNA isolated from peripheral 
blood mononuclear cells for amplification of different human 
IL-8 cDNA sequences was previously described (8). The cDNA 
sequences coding for the mature 72-residue (IL-872) or the 
N-terminal truncated 69-residue form (IL-83-72) were cloned 
into the eukaryotic pEAK8 vector (Edge Biosystems, 
Gaithersburg, MD, USA). The final vector coding for anti-FAP 
scFv antibody consisted of a promoter-leader cassette, coding 
for an 18-aa-long secretory leader and the Kozak sequence, the 
variable regions of the heavy chain, followed by a 15-aa linker 
and the variable regions of the light chain followed by c-myc- 
and His6 tag at the C-terminus. The vectors coding for IL-8-
derived immunocytokines were based on the vector described 
above with an additional 15-aa linker connecting the variable 
light chain with cDNA sequences of either IL-872 or IL83-72, 
followed by the tags at the C-terminus. All constructs were 
sequenced on both strands.
Expression, purification and characterization of antibody-derived 
constructs
Suspension-adapted HEK293 EBNA cells were cultured in 
DMEM/F12 medium (Life technologies, BRL) supplemented 
with 29 mM sodium bicarbonate, 10 mM HEPES, 2.5 mg/l 
insulin, 2.5 mg/l human transferrin, 0.1 mM proline, 0.1 mM 
diethanolamine and 1% FCS, at a density of 3 x 106 cells/ml. 
Transfection was performed in spinner flasks with an optimized 
calcium phosphate precipitation method (16, 17), using 2.5 µg 
DNA (99% construct DNA and 1% pEGFP C1, as a reporter for 
transfection efficiency) per 1 ml transfection medium. 
Approximately 80% transfection efficacy was observed. The 
supernatant was harvested 8-10 days after transfection, filtered 
through a 0.2 µm cellulose acetate membrane and purified via 
its C-terminal His6 tag using affinity chromatography (metal 
ion affinity chromatography on Zn2+ loaded HiTrap Chelating 
HP columns; Amersham, Freiburg, Germany). Potential 
endotoxin contamination was excluded by Limulus amebocyte 
assay (QCL 1000; BioWhittaker). Recombinant proteins were 
analyzed by SDS-PAGE as previously described (9) and protein 
bands were visualized by staining with Coomassie brilliant blue 
(Sigma, Munich, Germany). Proteins were transferred to PVDF 
membranes (Millipore, Bedford, MA) for Western blot analysis 
and blocked with 10% non-fat dry milk before incubation with 
rabbit anti-human IL-8 (0.2 µg/ml) antibody. Membranes were 
either stained by goat anti-rabbit IgG conjugated to HRP 
(1:3000; BioRad, Munich, Germany) or mouse anti-c-myc 9E10 
antibody (2 µg/ml), followed by biotinylated rabbit anti-mouse 
IgG conjugated to HRP (1:1000; BioRad) and visualized by 
chemiluminescence (ECL-Kit, Amersham).
Binding analysis
Flow cytometry was performed as previously described (9). In 
brief, 1 x 106 FAP- or mock-transfected cells were incubated 
(30 min, 4°C) with purified constructs at the specificity and 
concentration indicated. Cells were washed twice with PBS, 
incubated with anti-c-myc 9E10 or rabbit anti-IL-8 antibody 
and, finally, the complex visualized by adding PE-conjugated 
rabbit anti-mouse or goat anti-rabbit serum (dilution 1/100; 
DAKO, Hamburg, Germany). For each sample 10000 cells were 
counted and analyzed.
Binding of IL-8 fusion proteins was also assessed by ELISA. 
96-well flat-bottomed microtiter plates (MaxiSorp Immuno 
microwell plates, Nunc, Roskilde, Denmark) were coated 
(overnight, 4°C) with murine anti-idiotypic anti-FAP antibody 
(1 µg/ml) in 50 µl coating buffer per well. Plates were blocked 
with 1.5% gelatin in PBS and then the indicated reagents 
dissolved in PBS were added in serial dilutions and incubated 
for 1 h at room temperature (RT). After incubation with rabbit 
anti-human IL-8 antibody (0.5 µg/ml, 1 h, RT), biotinylated goat 
anti-rabbit serum (1:2000; 1 h, RT) and horseradish peroxidase 
(1:50000, 15 min, RT; Boehringer Mannheim, Germany) were 
added. Plates were developed by the addition of 
o-phenylenediamine substrate (Sigma, Deisenhofen, Germany). 
The reaction was stopped with 3 M HCl and the plates were then 
read on a Fluorimeter (Wallac 1420 Victor 2, Turku, Finland) at 
490 nm.
Fluorescence-based determination of PMN migration in vitro
PMNs were purified from the venous blood of healthy human 
donors as previously described (8) and labeled with 5 µg/ml 
calcein-AM (Molecular Probes, Eugene, OR). Cells were washed 
twice and resuspended in RPMI-1640 (without phenol red) and 
10% FCS at a concentration of 3.2 x 106 cells/ml. PMN 
migration was measured in triplicates using a non-disposable 
96-well ChemoTx-system with a polycarbonate filter (3.2 mm in 
diameter, 8 µm pore size, 8 mm2 exposed filter area per well; 
Neuroprobe, USA). Chemo-attractants were diluted in 0.1% 
PBS-HSA to a final volume of 29 µl per well. Pure PBS-HSA 
0.1% served as a control to determine random migration. In 
order to define the total fluorescence of the PMNs added to the 
top side of the filter and to correlate fluorescence with the 
number of PMNs that migrated, cell suspensions at www.cancerimmunity.org 9 of 10
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respectively per well, were placed directly in three wells in the 
bottom chamber. The filters were positioned on the loaded 
microplate and labeled PMNs were placed directly onto the top 
of the filters (25 µl/well). The plates were then incubated (at 
37°C, 5% CO2) for 60 minutes. Cells which had not migrated 
from the top of the filter were removed and migrated PMNs 
residing within and under the filter were spun down into the 
bottom chamber (450 x g, 10 min). The filter was removed and 
plates were read on a fluorimeter (model 1420, Victor 2; Wallac, 
Turku, Finland) at 485 nm. Statistical analyses were performed 
using Pearson's correlation coefficient (38).
Tumor model and treatment protocols
Adult male and female BALB/c nu/nu mice (6-8 wk; Charles 
River Laboratories) were used for efficacy assessment. Tumors 
were simultaneously engrafted by s.c. injection of 2 x 106 FAP- 
or mock-transfected HT1080 cells, respectively, at the opposite 
flanks of the animals. FAP antigen expression on xenografts was 
confirmed over four weeks. In the first trial, tumors were 
established in four groups of mice (three animals per group) and 
harvested 24 hours after i.v. injection of either 300 µg anti-FAP 
scFv-IL-872 (equivalent to 100 µg rhu IL-8), 200 µg anti-FAP 
scFv, 100 µg rhu IL-8, or PBS at equal volume. In a second trial, 
seven groups of mice (five animals per group) received five 
repeated i.v. injections of either 100 µg anti-FAP IgG TNF 
followed eight hours later by 300 µg anti-FAP scFv-IL-872, 
100 µg anti-FAP IgG TNF followed eight hours later by 100 µg 
rhu IL-8, 100 µg anti-FAP IgG followed eight hours later by 
100 µg rhu IL-8, 100 µg anti-FAP IgG or 100 µg rhu IL-8. 
Control mice received equal volumes of PBS alone. Treatment 
started when tumors reached 3 mm in diameter. Tumor growth 
and signs of treatment-related side effects were checked daily. 
The studies were approved by the local Animal Welfare 
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